Disease Focused

These include focused libraries of small-molecule compounds with potential biological activity towards certain diseases (such as Anti-Cancer Compound Library, Anti-Diabetic Compound Library, Anti-Cardiovascular Disease Compound Library, etc.).

Cat No.	product name
L1800	Anti-Infection Compound Library	A unique collection of 1326 anti-infective compounds including anti-bacterial, anti-fungi, anti-Human Cytomegalovirus (HCMV), anti-HIV, anti-SARS, anti-influenza, etc;	1326 compounds
L2130	Anti-Cancer Metabolism Compound Library	A unique collection of 1072 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);	1072 compounds
L4510	Anti-Parasitic Compound Library	Quantity: 358 well-chosen unique anti-parasitic small molecules;	358 compounds
L2151	Chemotherapy Drug Library		51 compounds
L5200	Anti-Metabolism Disease Compound Library	A unique collection of 1471 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS);	1471 compounds
L4520	Anti-Bacterial Compound Library	A unique collection of 1074 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;	1074 compounds
L1718	X Domain-Targeted Compound Library (CADD)	A unique collection of 463 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	463 compounds
L2170	Immuno-Oncology Compound Library	A unique collection of 340 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；	340 compounds
L4500	Anti-Fungal Compound Library	A unique collection of 157 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation.	157 compounds
L2190	Anti-Lung Cancer Compound Library	A unique collection of 704 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study；	704 compounds
L1711	Anti-COVID-19 Compound Library (CADD)	A unique collection of 362 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	362 compounds
L1719	Nsp15-Targeted Compound Library (CADD)	A unique collection of 470 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	470 compounds
L1714	RBD-Targeted Compound Library (CADD)	A unique collection of 206 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	206 compounds
L9810	Anti-Fibrosis Compound Library		981 compounds
L2140	Cancer Cell Differentiation Compound Library	A unique collection of 251 cancer cell differentiation inducing compounds for high throughput and high content screening;	251 compounds
L2180	Anti-Cancer Compound Library Plus	Quantity: well-chosen 958 anti-tumor compounds with unique structures;	958 compounds
L1716	PLpro-Targeted Compound Library (CADD)	A unique collection of 474 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	474 compounds
L2120	Anti-Cancer Clinical Compound Library	A unique collection of 1776 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS);	1776 compounds
L7100	Anti-Obesity Compound Library	A unique collection of 1176 anti-obesity compounds for high throughput and high content screening;	1176 compounds
L2150	Anti-Cancer Drug Library	A unique collection of 822 anticancer drugs for high throughput screening (HTS) and high content screening (HCS);	2217 compounds
L2620	Anti-Neurodegenerative Disease Compound Library	A unique collection of 902 compounds related to neurodegenerative diseases can be used for HTS or HCS；	902 compounds
L4700	Immunology/Inflammation Compound Library	A unique collection of 2769 anti-inflammation compounds effective for high throughput screening and high content screening.	2769 compounds
L8400	Hematonosis Compound Library	A unique collection of 126 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS);	126 compounds
L1710	Anti-COVID-19 Compound Library	A unique collection of 2448 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents；	2448 compounds
L1715	Nsp16-Targeted Compound Library (CADD)	A unique collection of 281 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	281 compounds
L1900	Anti-Diabetic Compound Library	A unique collection of 468 diabetes related compounds;	468 compounds
L5400	Anti-Cardiovascular Disease Compound Library	A unique collection of 987 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS);	987 compounds
L2152	Targeted Therapy Drug Library		116 compounds
L2191	Anti-Breast Cancer Compound Library		1052 compounds
L1700	Anti-Viral Compound Library	Quantity: A unique collection of 681 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;	681 compounds
L2110	Anti-Cancer Approved Drug Library	A unique collection of 1400 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);	1400 compounds
L9830	Anti-Parkinson's Disease Compound Library		184 compounds
L4660	Anti-Nervous System Disease Library	Quantity: well-chosen 935 compounds with unique structures targeting nervous system;	935 compounds
L2160	Anti-Cancer Active Compound Library	A unique collection of 1656 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);	1656 compounds
L1712	3CLpro-Targeted Compound Library (CADD)	A unique collection of 161 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	161 compounds
L2100	Anti-Cancer Compound Library	A unique collection of 4730 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);	4730 compounds
L2192	Anti-Pancreatic Cancer Compound Library		1162 compounds
L1717	RdRP-Targeted Compound Library (CADD)	A unique collection of 464 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	464 compounds
L4710	Nonsteroidal Anti-Inflammatory Compound Library	530 non-steroidal anti-inflammatory compounds for high-throughput and high-content screening.	530 compounds
L7110	Anti-Hypertension Compound Library		524 compounds
L1713	ACE2-Targeted Compound Library (CADD)	A unique collection of 462 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening;	462 compounds